Patient Benefits in the Treatment of Psoriasis: Long-term Outcomes in German Routine Care 2007–2014
Standard
Patient Benefits in the Treatment of Psoriasis: Long-term Outcomes in German Routine Care 2007–2014. / Radtke, M A; Langenbruch, A; Jacobi, A; Schaarschmidt, M-L; Augustin, M.
in: J EUR ACAD DERMATOL, Jahrgang 30, Nr. 10, 10.2016, S. 1829-1833.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Patient Benefits in the Treatment of Psoriasis: Long-term Outcomes in German Routine Care 2007–2014
AU - Radtke, M A
AU - Langenbruch, A
AU - Jacobi, A
AU - Schaarschmidt, M-L
AU - Augustin, M
N1 - © 2016 European Academy of Dermatology and Venereology.
PY - 2016/10
Y1 - 2016/10
N2 - BACKGROUND: Psoriasis is associated with significant patient burden. Few studies have specifically measured patient preferences and benefits.OBJECTIVES: Outcomes assessment using the Patient Benefit Index (PBI) in nationwide psoriasis surveys comparing health care in 2007 and 2014.METHODS: This was a non-interventional, cross-sectional survey conducted in 2007 and 2014 in randomly selected dermatological practices and clinics recording by a) physicians: comorbidity, clinical severity (PASI, GCA), and b) patients: quality of life (DLQI, EQ-5D), patient-relevant therapeutic benefits (PBI) and previous and curent treatments.RESULTS: In 2014, a total of n = 1265 patients (43.4% female, mean age 51.9 ± 14.3 years.; mean disease duration 21.6 ± 15.4 years.) were included. Overall PBI was 2.8 ± 1.1. A total of 91.6% of patients showed a more than minimum clinically relevant benefit (PBI>1). Patients treated with biologics and biologics combined with conventional systemics showed the highest benefit compared to patients with conventional systemic treatment and patients treated with topical steroids. In comparison with the 2007 survey (n = 2009), there was an increase in PBI from 2.5 ± 1.1 to 2.8 ± 1.1 and a gain of patients with high benefits (PBI ≥3) by 30% (38.5% vs. 49.4%).CONCLUSION: In German routine care, psoriasis patients have shown increased therapeutic benefits over time with highest benefits deriving from biologics combined with systemics.
AB - BACKGROUND: Psoriasis is associated with significant patient burden. Few studies have specifically measured patient preferences and benefits.OBJECTIVES: Outcomes assessment using the Patient Benefit Index (PBI) in nationwide psoriasis surveys comparing health care in 2007 and 2014.METHODS: This was a non-interventional, cross-sectional survey conducted in 2007 and 2014 in randomly selected dermatological practices and clinics recording by a) physicians: comorbidity, clinical severity (PASI, GCA), and b) patients: quality of life (DLQI, EQ-5D), patient-relevant therapeutic benefits (PBI) and previous and curent treatments.RESULTS: In 2014, a total of n = 1265 patients (43.4% female, mean age 51.9 ± 14.3 years.; mean disease duration 21.6 ± 15.4 years.) were included. Overall PBI was 2.8 ± 1.1. A total of 91.6% of patients showed a more than minimum clinically relevant benefit (PBI>1). Patients treated with biologics and biologics combined with conventional systemics showed the highest benefit compared to patients with conventional systemic treatment and patients treated with topical steroids. In comparison with the 2007 survey (n = 2009), there was an increase in PBI from 2.5 ± 1.1 to 2.8 ± 1.1 and a gain of patients with high benefits (PBI ≥3) by 30% (38.5% vs. 49.4%).CONCLUSION: In German routine care, psoriasis patients have shown increased therapeutic benefits over time with highest benefits deriving from biologics combined with systemics.
U2 - 10.1111/jdv.13764
DO - 10.1111/jdv.13764
M3 - SCORING: Journal article
C2 - 27440750
VL - 30
SP - 1829
EP - 1833
JO - J EUR ACAD DERMATOL
JF - J EUR ACAD DERMATOL
SN - 0926-9959
IS - 10
ER -
